Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2012

View Archived Issues

Studies examine effects of aleglitazar on lipoproteins and aspirin-induced renal dysfunction

First-in-class oxaborole antibiotic shows potential to treat lung infections

AZD-8055 analogue shows promise to treat of hormone therapy-resistant tumors

Ketolide displays activity against Neisseria gonorrhoeae

FORMA Therapeutics presents novel Nampt inhibitors

Novel mouse model of atherosclerotic plaque rupture designed in Australia

DNA-intercalating antibacterial displays broad range of activity

Bionure neuroprotective drug set to enter clinic next year

Phase IIb study of eteplirsen meets primary endpoint

Forest Laboratories acquires intellectual property from Janssen

Astellas and Vical finalize design of pivotal CMV vaccine trial

First stage of phase III study of Reolysin completes enrollment

Hutchinson MediPharma presents potent dual PI3K/mTOR inhibitor

Phase III palifosfamide study advances

Novel protein kinase inhibitors reported by Ambit Biosciences

Gruenenthal discloses new bradykinin B1 receptor antagonists

FDA approves transdermal rotigotine patch for PD and RLS

Amgen and AstraZeneca to jointly develop inflammation portfolio candidates

Onyx Pharmaceuticals reports phase III regorafenib data

Medistem stem cell product to be evaluated in traumatic brain injury

Ajinomoto in-licenses IBAT inhibitor

Scripps Research Institute obtains funds to study new pathway in lymphoma

GSK gives update on phase III Harmony program

Marina Biotech completes dosing second cohort in START-FAP trial

AlloCure raises funds to support AC-607 development

Pfizer drug approved in Japan for ALK-positive NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...